APLNR and neoplasm: In summary because few tumor EC-specific antigens have been identified, targeting APJ as well as integrin αvβ3 as previously reported, which integrin binding peptide RGD conjugated nanoparticles accumulate and deliver drugs to ECs in tumor effectively, [24], [25] will be useful to disrupt blood vessel formation specifically in tumors.